Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $11.16 billion. The enterprise value is $11.78 billion.

Market Cap	11.16B
Enterprise Value	11.78B

Important Dates

The next estimated earnings date is Thursday, August 6, 2026, after market close.

Earnings Date	Aug 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Cytokinetics has 135.77 million shares outstanding. The number of shares has increased by 4.46% in one year.

Current Share Class	135.77M
Shares Outstanding	135.77M
Shares Change (YoY)	+4.46%
Shares Change (QoQ)	+2.64%
Owned by Insiders (%)	0.42%
Owned by Institutions (%)	108.69%
Float	135.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	105.46
Forward PS	78.55
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	111.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.21

Current Ratio	4.21
Quick Ratio	4.14
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-5.60

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-31.54%
Return on Invested Capital (ROIC)	-62.88%
Return on Capital Employed (ROCE)	-59.60%
Weighted Average Cost of Capital (WACC)	6.60%
Revenue Per Employee	$157,229
Profits Per Employee	-$1.23M
Employee Count	673
Asset Turnover	0.08
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +148.23% in the last 52 weeks. The beta is 0.43, so Cytokinetics's price volatility has been lower than the market average.

Beta (5Y)	0.43
52-Week Price Change	+148.23%
50-Day Moving Average	72.44
200-Day Moving Average	64.45
Relative Strength Index (RSI)	68.77
Average Volume (20 Days)	2,324,302

Short Selling Information

The latest short interest is 15.50 million, so 11.42% of the outstanding shares have been sold short.

Short Interest	15.50M
Short Previous Month	16.46M
Short % of Shares Out	11.42%
Short % of Float	11.47%
Short Ratio (days to cover)	4.40

Income Statement

In the last 12 months, Cytokinetics had revenue of $105.82 million and -$829.61 million in losses. Loss per share was -$6.84.

Revenue	105.82M
Gross Profit	-307.63M
Operating Income	-640.25M
Pretax Income	-829.61M
Net Income	-829.61M
EBITDA	-629.04M
EBIT	-640.25M
Loss Per Share	-$6.84

Full Income Statement

Balance Sheet

The company has $818.55 million in cash and $1.44 billion in debt, giving a net cash position of -$625.07 million or -$4.60 per share.

Cash & Cash Equivalents	818.55M
Total Debt	1.44B
Net Cash	-625.07M
Net Cash Per Share	-$4.60
Equity (Book Value)	-826.57M
Book Value Per Share	-6.65
Working Capital	640.28M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$523.85 million and capital expenditures -$25.07 million, giving a free cash flow of -$548.92 million.

Operating Cash Flow	-523.85M
Capital Expenditures	-25.07M
Depreciation & Amortization	11.20M
Net Borrowing	316.10M
Free Cash Flow	-548.92M
FCF Per Share	-$4.04

Full Cash Flow Statement

Margins

Gross Margin	-290.73%
Operating Margin	-605.06%
Pretax Margin	-784.02%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.46%
Shareholder Yield	-4.46%
Earnings Yield	-7.43%
FCF Yield	-4.92%

Analyst Forecast

The average price target for Cytokinetics is $105.60, which is 28.48% higher than the current price. The consensus rating is "Buy".

Price Target	$105.60
Price Target Difference	28.48%
Analyst Consensus	Buy
Analyst Count	22
Revenue Growth Forecast (3Y)	112.72%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.

Last Split Date	Jun 25, 2013
Split Type	Reverse
Split Ratio	1:6

Scores

Cytokinetics has an Altman Z-Score of -3.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.29
Piotroski F-Score	3